All In Biotech

Drug Trial Radar · NCT06401213

A First-in-Human Safety Trial of MTX-463

MTX-463-I101: A Phase 1 Randomized, Double-Blind, Dose-Escalating Study to Assess the Safety, Tolerability, and Pharmacokinetics of MTX-463 in Healthy Adults

Last checked: Nov 19, 2026Latest source record: Jan 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

56

Actual

Start

Apr 15, 2024

Primary completion

Nov 15, 2024

Study completion Nov 15, 2024

Sponsor

Lead sponsor
Mediar TherapeuticsIndustry
Sponsor type
Industry
Collaborators
ICON plc
First posted
May 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and PK of single and multiple ascending doses of MTX-463 administered in healthy adults.

Conditions

  • Healthy

Interventions

  • MTX-463Biological

    MTX-463 is an immunoglobin G1 (IgG1) monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1). WISP1 (aka CCN-4) is a matricellular protein that appears to be upregulated locally in response to certain chronic diseases and malignancies.

  • PlaceboOther

    Matching Placebo-- Normal Saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Related Adverse Events in healthy volunteersTime frame: Through Day 60 (SAD Cohort) or Day 82 (MAD Cohort)
  2. MTX-463 PK by dose will be evaluated for Cmax, as feasibleTime frame: Through Day 60 (SAD Cohort) or Day 82 (MAD Cohort)
  3. Serum sample results will be summarized for presence of Anti-Drug Antibodies during the SAD and MAD portions of the study.Time frame: Through Day 60 (SAD Cohort) or Day 82 (MAD Cohort)
  4. MTX-463 PK by dose will be evaluated for AUC0-t, as feasible.Time frame: Through Day 60 (SAD Cohort) or Day 82 (MAD Cohort)
  5. MTX-463 PK by dose will be evaluated for AUC0-tau (MAD only), as feasibleTime frame: Through Day 82 (MAD Cohort)
  6. MTX-463 PK by dose will be evaluated for AUC0-∞, as feasibleTime frame: Through Day 60 (SAD Cohort) or Day 82 (MAD Cohort)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ICON

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.